Date: 2013-04-09
Type of information: Collaboration agreement
Compound: Tykerb® (lapatinib)
Company: Eddingpharm (China) GSK China
Therapeutic area: Cancer - Oncology
Type agreement: commercialisation
distribution
Action mechanism: kinase inhibitor. Lapatinib is a small molecular reversible inhibitor of tyrosine kinase.
Disease: advanced or metastatic breast cancer
Details: * On April 9, 2013, Eddingpharm, a Chinese specialty pharmaceutical company, has announced a collaboration agreement with GSK China, whereby Eddingpharm will acquire from GSK the exclusive right in mainland China to import, market, promote, distribute and sell Tykerb®, a treatment for advanced or metastatic breast cancer that was recently approved by the China State Food and Drug Administration (SFDA).
Tykerb® is used, in combination with capecitabine, for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress HER2 and who have received prior therapy with an anthracycline, a taxane and trastuzumab.
Financial terms:
Latest news:
